The persistent director buying caught my eye, but I'm puzzled as to why?
I would have thought it would be more practical for a cashed-up director to acquire scrip via a placement or rights issue so they could buy in below market price.
Interesting pedigree for the XBL management - there seems to be some solid comercial background to the directors.
R/happy
XBL
xceed biotechnology ltd
